Mechanism Of Action:
Erlotinib is belonged to the group ‘EGFR inhibitors’. It can block EGFRs, which is found on some tumor cells, as a result of this block, the tumor cells can no longer receive the messages needed for growing and for spreading (metastasis). Leads to stop growing and spreading cancer cells through the body.
Indication:
- it’s a cancer medicine used in non‑small-cell lung cancer (NSCLC) that is advanced or metastatic. It can be used for:
-
- previously untreated patients whose cancerous cells have certain changes (‘activating mutations’) in the gene for a protein called epidermal growth factor receptor (EGFR);
-
- Patients with EGFR activating mutations whose disease is stable after initial chemotherapy. Stable means that the cancer has neither improved nor worsened with chemotherapy;
- patients with EGFR activating mutations in whom previous chemotherapy has not worked;
- Patients without EGFR activating mutations in whom previous chemotherapy has not worked and other treatments are unsuitable.
- It is also used in patients with metastatic pancreatic cancer
